Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 6,939 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 6,939 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the completion of the sale, the chief financial officer owned 52,120 shares of the company’s stock, valued at $11,874,499.60. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The shares were sold at an average price of $230.40, for a total transaction of $430,156.80.
• On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The stock was sold at an average price of $237.56, for a total transaction of $573,232.28.
• On Tuesday, January 27th, Michael Burkes Brophy sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $188,575.52.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The shares were sold at an average price of $242.54, for a total value of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,621,553.52.

Natera Trading Down 9.7%

NASDAQ:NTRA opened at $205.61 on Thursday. The company has a market cap of $28.44 billion, a price-to-earnings ratio of -89.79 and a beta of 1.64. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The stock has a fifty day simple moving average of $234.95 and a 200-day simple moving average of $195.74.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same period in the prior year, the business earned ($0.26) EPS. The company’s quarterly revenue was up 34.7% on a year-over-year basis. As a group, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera submitted a Premarket Approval (PMA) to the FDA for Signatera CDx to detect minimal residual disease (MRD) in bladder cancer after positive phase‑3 results — a regulatory win that could create a companion diagnostic revenue stream and improve clinical adoption/reimbursement if approved. Read More.
• Neutral Sentiment: Multiple non‑executive insiders also sold shares this week (Solomon Moshkevich and John Fesko each trimmed small single‑digit percentages of their holdings). These appear to be modest, routine dispositions versus strategic exits but add to selling pressure. Read More.
• Negative Sentiment: CEO Steven Chapman sold 85,299 shares on Feb 2 (~40% reduction in his holding) for a proceeds block of roughly $19.7M — a material insider disposition that investors often view negatively. Read More.
• Negative Sentiment: Additional executive sales this week: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), each trimming double‑digit or mid‑single digit ownership percentages — reinforcing near‑term downward pressure on the stock. Read More. Read More.

Analyst Ratings Changes

Several research firms have commented on NTRA. Piper Sandler raised their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. UBS Group upped their price objective on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, Citigroup assumed coverage on shares of Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Horizon Investments LLC acquired a new stake in Natera in the third quarter valued at approximately $32,000. Hilltop National Bank acquired a new stake in shares of Natera in the 2nd quarter worth $33,000. Sound Income Strategies LLC grew its stake in Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after buying an additional 110 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in Natera during the 4th quarter valued at about $41,000. Finally, Quent Capital LLC purchased a new stake in Natera in the third quarter valued at about $46,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.